company background image
DMTK

DermTech NasdaqCM:DMTK Stock Report

Last Price

US$5.57

Market Cap

US$168.3m

7D

-10.2%

1Y

-56.1%

Updated

05 Feb, 2023

Data

Company Financials +

DMTK Stock Overview

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States.

DMTK fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

DermTech, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DermTech
Historical stock prices
Current Share PriceUS$5.57
52 Week HighUS$16.33
52 Week LowUS$1.55
Beta1.76
1 Month Change161.50%
3 Month Change201.08%
1 Year Change-56.14%
3 Year Change-59.43%
5 Year Changen/a
Change since IPO1.74%

Recent News & Updates

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Recent updates

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08
Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11
Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10
Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02
Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics

Sep 15

We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth

Sep 03
We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth

DermTech: Transforming The Melanoma Diagnosis Landscape

Aug 31

DermTech: Becoming More Appealing, Despite Nosebleed Valuation

Aug 09

DermTech appoints former Myriad Genetics executive as new chief medical officer

Jun 16

We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 05
We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech initiated buy at BTIG on the potential of PLA test

May 03

DermTech rises 18% on report Cigna covering early melanoma detection test

Apr 27

Did DermTech, Inc. (NASDAQ:DMTK) Insiders Buy Up More Shares?

Feb 11
Did DermTech, Inc. (NASDAQ:DMTK) Insiders Buy Up More Shares?

DermTech's melanoma testing patch included in NCCN Guidelines

Jan 13

DermTech proposes public offering; shares -5.7%

Jan 06

DermTech receives positive medical coverage by Geisinger

Dec 30

DermTech: Stickers To Diagnose Cancer

Dec 22

DermTech inks agreement with Illinois-based Blue Cross Blue Shield

Nov 20

Shareholder Returns

DMTKUS BiotechsUS Market
7D-10.2%-0.8%1.7%
1Y-56.1%4.4%-9.6%

Return vs Industry: DMTK underperformed the US Biotechs industry which returned 4.4% over the past year.

Return vs Market: DMTK underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is DMTK's price volatile compared to industry and market?
DMTK volatility
DMTK Average Weekly Movement23.9%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: DMTK is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: DMTK's weekly volatility has increased from 18% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a257John Dobakhttps://www.dermtech.com

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways.

DermTech, Inc. Fundamentals Summary

How do DermTech's earnings and revenue compare to its market cap?
DMTK fundamental statistics
Market CapUS$168.30m
Earnings (TTM)-US$114.51m
Revenue (TTM)US$14.69m

11.5x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DMTK income statement (TTM)
RevenueUS$14.69m
Cost of RevenueUS$13.56m
Gross ProfitUS$1.13m
Other ExpensesUS$115.64m
Earnings-US$114.51m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.79
Gross Margin7.68%
Net Profit Margin-779.58%
Debt/Equity Ratio0%

How did DMTK perform over the long term?

See historical performance and comparison